Back to Search
Start Over
Efficacy and Safety of Intravenous Labetalol in Acute Hypertensive Crisis in Children.
- Source :
-
Indian journal of pediatrics [Indian J Pediatr] 2022 Jan; Vol. 89 (1), pp. 7-12. Date of Electronic Publication: 2021 Apr 24. - Publication Year :
- 2022
-
Abstract
- Objective: To determine the efficacy and safety of intravenous (IV) labetalol in the management of hypertensive crisis in children.<br />Methods: A retrospective chart review of 56 consecutive children (age > 1 mo to ≤ 12 y) with hypertensive crisis admitted to a pediatric intensive care unit (PICU) from July 2009 to 2019.<br />Results: The proportion of children attaining the primary endpoint (target 95th percentile in > 12 to ≤ 48 h) was significantly more in the group receiving labetalol as first-line or add-on (n = 23) as compared to those not receiving labetalol (n = 33) (62% vs. 30.3%, p = 0.03). Higher proportion of neurological recovery was seen in the labetalol group (56.2% vs. 18.7%, p = 0.02). The proportion of children with hypotension before 12 h was similar in both treatment groups (13% vs. 15%, p = 0.82). The practice variations between two periods of 5 y each (2009-2013 and 2014-2019) showed significantly more use of labetalol in the latter cohort (53% for 2014-2019 vs. 25% for 2009-2013, p = 0.03).<br />Conclusion: Labetalol, when used alone or as an add-on drug, was more efficacious than IV nitroprusside/nitroglycerine in attaining the primary endpoint in children up to ≤ 12 y of age with hypertensive crisis. Labetalol was safe and associated with higher neurological recovery.<br /> (© 2021. Dr. K C Chaudhuri Foundation.)
Details
- Language :
- English
- ISSN :
- 0973-7693
- Volume :
- 89
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Indian journal of pediatrics
- Publication Type :
- Academic Journal
- Accession number :
- 33893609
- Full Text :
- https://doi.org/10.1007/s12098-021-03707-7